---
document_datetime: 2025-11-23 08:10:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-ratiopharm.html
document_name: clopidogrel-ratiopharm.html
version: success
processing_time: 0.1298042
conversion_datetime: 2025-12-27 09:50:13.21072
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Clopidogrel ratiopharm

[RSS](/en/individual-human-medicine.xml/65789)

##### Authorised

This medicine is authorised for use in the European Union

clopidogrel

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Clopidogrel ratiopharm](#news-on)
- [Related information](#related-information-1093)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Clopidogrel ratiopharm. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Clopidogrel ratiopharm.

For practical information about using Clopidogrel ratiopharm, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Clopidogrel ratiopharm and what is it used for?

Clopidogrel ratiopharm is a blood-thinning medicine used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). Clopidogrel ratiopharm can be given to the following groups of patients:

- patients who have recently had a myocardial infarction (heart attack). Clopidogrel ratiopharm can be started between a few days and 35 days after the attack;
- patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Clopidogrel ratiopharm can be started between seven days and six months after the stroke;
- patients with peripheral arterial disease (problems with blood flow in the arteries);
- patients with acute coronary syndrome (a condition in which blood supply to the heart is reduced), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up); the medicine should be given with aspirin (another medicine that prevents blood clots). Clopidogrel ratiopharm can be used in patients who are having a heart attack with 'ST segment elevation' (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment. It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or have had a 'non-Q-wave' myocardial infarction.

Clopidogrel ratiopharm can also be used to prevent problems caused by blood clots in adults with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin. It is used in patients who have at least one risk factor for events such as a heart attack or stroke, cannot take vitamin-K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.

Clopidogrel ratiopharm is a 'generic medicine'. This means that Clopidogrel ratiopharm is similar to a 'reference medicine' already authorised in the European Union (EU) called Plavix.

Clopidogrel ratiopharm contains the active substance clopidogrel.

## How is Clopidogrel ratiopharm used?

Clopidogrel ratiopharm is available as tablets containing 75 mg clopidogrel. The standard dose is one 75-mg tablet once a day.

In acute coronary syndrome, treatment generally starts with a loading dose of four tablets. This is then followed by the standard 75-mg dose once a day for at least four weeks (in 'ST segment elevation' myocardial infarction) or for up to 12 months (in unstable angina or 'non-Q-wave' myocardial infarction). In acute coronary syndrome and atrial fibrillation, Clopidogrel ratiopharm is used together with aspirin, the dose of which should not be higher than 100 mg.

Clopidogrel ratiopharm can only be obtained with a prescription.

## How does Clopidogrel ratiopharm work?

The active substance in Clopidogrel ratiopharm, clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. This stops the platelets becoming 'sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.

## How has Clopidogrel ratiopharm been studied?

Because Clopidogrel ratiopharm is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Clopidogrel ratiopharm?

Because Clopidogrel ratiopharm is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Clopidogrel ratiopharm approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel ratiopharm has been shown to have comparable quality and to be bioequivalent to Plavix. Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk. The Committee recommended that Clopidogrel ratiopharm be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Clopidogrel ratiopharm?

A risk management plan has been developed to ensure that Clopidogrel ratiopharm is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Clopidogrel ratiopharm, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the .

## Other information about Clopidogrel ratiopharm

The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel ratiopharm on 19 February 2015.

For more information about treatment with Clopidogrel ratiopharm, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Clopidogrel ratiopharm : EPAR - Summary for the public

Reference Number: EMA/3112/2015

English (EN) (98.38 KB - PDF)

**First published:** 11/03/2015

**Last updated:** 11/03/2015

[View](/en/documents/overview/clopidogrel-ratiopharm-epar-summary-public_en.pdf-0)

[Other languages (22)](#file-language-dropdown-770)

български (BG) (134.22 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/bg/documents/overview/clopidogrel-ratiopharm-epar-summary-public_bg.pdf-0)

español (ES) (132.8 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/es/documents/overview/clopidogrel-ratiopharm-epar-summary-public_es.pdf-0)

čeština (CS) (130.2 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/cs/documents/overview/clopidogrel-ratiopharm-epar-summary-public_cs.pdf-0)

dansk (DA) (127.87 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/da/documents/overview/clopidogrel-ratiopharm-epar-summary-public_da.pdf-0)

Deutsch (DE) (131.62 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/de/documents/overview/clopidogrel-ratiopharm-epar-summary-public_de.pdf-0)

eesti keel (ET) (124.27 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/et/documents/overview/clopidogrel-ratiopharm-epar-summary-public_et.pdf-0)

ελληνικά (EL) (137.27 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/el/documents/overview/clopidogrel-ratiopharm-epar-summary-public_el.pdf-0)

français (FR) (134.89 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/fr/documents/overview/clopidogrel-ratiopharm-epar-summary-public_fr.pdf-0)

hrvatski (HR) (127.12 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/hr/documents/overview/clopidogrel-ratiopharm-epar-summary-public_hr.pdf)

italiano (IT) (126.29 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/it/documents/overview/clopidogrel-ratiopharm-epar-summary-public_it.pdf-0)

latviešu valoda (LV) (142.63 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/lv/documents/overview/clopidogrel-ratiopharm-epar-summary-public_lv.pdf-0)

lietuvių kalba (LT) (128.02 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/lt/documents/overview/clopidogrel-ratiopharm-epar-summary-public_lt.pdf-0)

magyar (HU) (130.69 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/hu/documents/overview/clopidogrel-ratiopharm-epar-summary-public_hu.pdf-0)

Malti (MT) (133.46 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/mt/documents/overview/clopidogrel-ratiopharm-epar-summary-public_mt.pdf-0)

Nederlands (NL) (127.44 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/nl/documents/overview/clopidogrel-ratiopharm-epar-summary-public_nl.pdf-0)

polski (PL) (129.97 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/pl/documents/overview/clopidogrel-ratiopharm-epar-summary-public_pl.pdf-0)

português (PT) (132.16 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/pt/documents/overview/clopidogrel-ratiopharm-epar-summary-public_pt.pdf-0)

română (RO) (120.54 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/ro/documents/overview/clopidogrel-ratiopharm-epar-summary-public_ro.pdf-0)

slovenčina (SK) (129.36 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/sk/documents/overview/clopidogrel-ratiopharm-epar-summary-public_sk.pdf-0)

slovenščina (SL) (126.16 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/sl/documents/overview/clopidogrel-ratiopharm-epar-summary-public_sl.pdf-0)

Suomi (FI) (126.16 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/fi/documents/overview/clopidogrel-ratiopharm-epar-summary-public_fi.pdf-0)

svenska (SV) (126.57 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/sv/documents/overview/clopidogrel-ratiopharm-epar-summary-public_sv.pdf-0)

Clopidogrel-ratiopharm : EPAR - Risk-management-plan summary

English (EN) (351.84 KB - PDF)

**First published:** 11/03/2015

**Last updated:** 26/03/2024

[View](/en/documents/rmp-summary/clopidogrel-ratiopharm-epar-risk-management-plan-summary_en.pdf)

## Product information

Clopidogrel ratiopharm : EPAR - Product information

English (EN) (555.41 KB - PDF)

**First published:** 11/03/2015

**Last updated:** 26/03/2024

[View](/en/documents/product-information/clopidogrel-ratiopharm-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-590)

български (BG) (772.59 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/bg/documents/product-information/clopidogrel-ratiopharm-epar-product-information_bg.pdf)

español (ES) (548.31 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/es/documents/product-information/clopidogrel-ratiopharm-epar-product-information_es.pdf)

čeština (CS) (682.69 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/cs/documents/product-information/clopidogrel-ratiopharm-epar-product-information_cs.pdf)

dansk (DA) (567.23 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/da/documents/product-information/clopidogrel-ratiopharm-epar-product-information_da.pdf)

Deutsch (DE) (597.4 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/de/documents/product-information/clopidogrel-ratiopharm-epar-product-information_de.pdf)

eesti keel (ET) (596.96 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/et/documents/product-information/clopidogrel-ratiopharm-epar-product-information_et.pdf)

ελληνικά (EL) (721.55 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/el/documents/product-information/clopidogrel-ratiopharm-epar-product-information_el.pdf)

français (FR) (602.5 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/fr/documents/product-information/clopidogrel-ratiopharm-epar-product-information_fr.pdf)

hrvatski (HR) (648.47 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/hr/documents/product-information/clopidogrel-ratiopharm-epar-product-information_hr.pdf)

íslenska (IS) (636.35 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/is/documents/product-information/clopidogrel-ratiopharm-epar-product-information_is.pdf)

italiano (IT) (651.02 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/it/documents/product-information/clopidogrel-ratiopharm-epar-product-information_it.pdf)

latviešu valoda (LV) (684.77 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/lv/documents/product-information/clopidogrel-ratiopharm-epar-product-information_lv.pdf)

lietuvių kalba (LT) (685.82 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/lt/documents/product-information/clopidogrel-ratiopharm-epar-product-information_lt.pdf)

magyar (HU) (635.58 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/hu/documents/product-information/clopidogrel-ratiopharm-epar-product-information_hu.pdf)

Malti (MT) (798.58 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/mt/documents/product-information/clopidogrel-ratiopharm-epar-product-information_mt.pdf)

Nederlands (NL) (545.87 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/nl/documents/product-information/clopidogrel-ratiopharm-epar-product-information_nl.pdf)

norsk (NO) (390.68 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/no/documents/product-information/clopidogrel-ratiopharm-epar-product-information_no.pdf)

polski (PL) (722.96 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/pl/documents/product-information/clopidogrel-ratiopharm-epar-product-information_pl.pdf)

português (PT) (564.04 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/pt/documents/product-information/clopidogrel-ratiopharm-epar-product-information_pt.pdf)

română (RO) (698.56 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/ro/documents/product-information/clopidogrel-ratiopharm-epar-product-information_ro.pdf)

slovenčina (SK) (648.65 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/sk/documents/product-information/clopidogrel-ratiopharm-epar-product-information_sk.pdf)

slovenščina (SL) (674.36 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/sl/documents/product-information/clopidogrel-ratiopharm-epar-product-information_sl.pdf)

Suomi (FI) (565.06 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/fi/documents/product-information/clopidogrel-ratiopharm-epar-product-information_fi.pdf)

svenska (SV) (571.25 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

26/03/2024

[View](/sv/documents/product-information/clopidogrel-ratiopharm-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0024/G 21/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Clopidogrel ratiopharm : EPAR - All Authorised presentations

English (EN) (702.75 KB - PDF)

**First published:** 11/03/2015

**Last updated:** 11/03/2015

[View](/en/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-513)

български (BG) (41.42 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/bg/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_bg.pdf)

español (ES) (73.09 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/es/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.27 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/cs/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.58 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/da/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (38.98 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/de/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.69 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/et/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.48 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/el/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_el.pdf)

français (FR) (40.27 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/fr/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.39 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/hr/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (36.74 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/is/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_is.pdf)

italiano (IT) (37.85 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/it/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.82 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/lv/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (38.66 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/lt/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.24 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/hu/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.51 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/mt/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (37.22 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/nl/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (37.55 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/no/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_no.pdf)

polski (PL) (36.38 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/pl/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_pl.pdf)

português (PT) (37.66 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/pt/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.72 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/ro/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (38.9 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/sk/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/sl/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (37.73 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/fi/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.62 KB - PDF)

**First published:**

11/03/2015

**Last updated:**

11/03/2015

[View](/sv/documents/all-authorised-presentations/clopidogrel-ratiopharm-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Clopidogrel ratiopharm Active substance clopidogrel (as hydrogen sulfate) International non-proprietary name (INN) or common name clopidogrel Therapeutic area (MeSH)

- Myocardial Infarction
- Acute Coronary Syndrome
- Peripheral Vascular Diseases
- Stroke

Anatomical therapeutic chemical (ATC) code B01AC04

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Secondary prevention of atherothrombotic events Clopidogrel is indicated in:

- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Adult patients suffering from acute coronary syndrome:
    - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
    - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

## Authorisation details

EMA product number EMEA/H/C/004006

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5 2031GA Haarlem The Netherlands

Opinion adopted 18/12/2014 Marketing authorisation issued 18/02/2015 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Clopidogrel ratiopharm : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (183.75 KB - PDF)

**First published:** 28/09/2015

**Last updated:** 26/03/2024

[View](/en/documents/procedural-steps-after/clopidogrel-ratiopharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Clopidogrel ratiopharm : EPAR - Public assessment report

Adopted

Reference Number: EMA/63392/2015

English (EN) (702.75 KB - PDF)

**First published:** 11/03/2015

**Last updated:** 11/03/2015

[View](/en/documents/assessment-report/clopidogrel-ratiopharm-epar-public-assessment-report_en.pdf-0)

CHMP summary of positive opinion for Clopidogrel ratiopharm

Adopted

Reference Number: EMA/CHMP/476872/2014

English (EN) (81.21 KB - PDF)

**First published:** 19/12/2014

**Last updated:** 19/12/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-ratiopharm_en.pdf)

#### News on Clopidogrel ratiopharm

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 December 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-december-2014) 19/12/2014

#### Related information

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/03/2024

## Share this page

[Back to top](#main-content)